Outcomes of stage IV melanoma in the era of immunotherapy: a National Cancer Database (NCDB) analysis from 2014 to 2016.
Immunotherapy
Melanoma
Journal
Journal for immunotherapy of cancer
ISSN: 2051-1426
Titre abrégé: J Immunother Cancer
Pays: England
ID NLM: 101620585
Informations de publication
Date de publication:
08 2022
08 2022
Historique:
accepted:
08
07
2022
entrez:
23
8
2022
pubmed:
24
8
2022
medline:
26
8
2022
Statut:
ppublish
Résumé
To evaluate factors affecting the utilization of immunotherapy and to stratify results based on the approval of ipilimumab in 2011 and programmed death-1 inhibitors in 2014, an analysis of available data from the National Cancer Database (NCDB) was performed. The NCDB was analyzed to identify patients with stage IV melanoma from 2004 to 2016. Patients were categorized during the time periods 2004-2010, 2011-2014, and 2015-2016. Overall survival (OS) was analyzed by Kaplan-Meier, log-rank, and Cox proportional hazard models; IO status was analyzed using logistic regression. 24,544 patients were analyzed. Overall, 5238 patients (21.3%) who received IO had improved median OS compared with those who did not (20.2 months vs 7.4 months; p<0.0001). Between 2004 and 2010, 9.7% received immunotherapy; from 2011 to 2014, 21.9% received immunotherapy; and from 2015 to 2016, 43.5% received immunotherapy. Three-year OS significantly improved in patients treated with IO across treatment years: 31% (95% CI 29% to 34%) from 2004 to 2010, 35% (95% CI 33% to 37%) from 2011 to 2014, and 46% (95% CI 44% to 48%) from 2015 to 2016 (p<0.0001). Survival was worse in patients who did not receive IO during these treatment years: 16% (15%-17%), 21% (20%-22%), and 27% (25%-28%), respectively. In the overall cohort, age <65 years, female gender, private insurance, no comorbidities, residence in metropolitan area, and treatment at academic centers were associated with better OS (p<0.0001 for all). In the multivariate analysis, receipt of IO from 2015 to 2016 was associated with age <65 years (OR 1.27, 95% CI 1.08 to 1.50), African American race (OR 5.88, 95% CI 1.60 to 28.58), lack of comorbidities (OR 1.43, 95% CI 1.23 to 1.66), and treatment at academic centers (OR 1.44, 95% CI 1.26 to 1.65) (p<0.05 for all). OS improved in patients with stage IV melanoma receiving IO, with the highest OS rate in 2015-2016. Our findings, which represent a real-world population, are slightly lower than recent trials, such as KEYNOTE-006 and CheckMate 067. Significant socioeconomic factors may impact receipt of IO and survival.
Sections du résumé
BACKGROUND
To evaluate factors affecting the utilization of immunotherapy and to stratify results based on the approval of ipilimumab in 2011 and programmed death-1 inhibitors in 2014, an analysis of available data from the National Cancer Database (NCDB) was performed.
METHODS
The NCDB was analyzed to identify patients with stage IV melanoma from 2004 to 2016. Patients were categorized during the time periods 2004-2010, 2011-2014, and 2015-2016. Overall survival (OS) was analyzed by Kaplan-Meier, log-rank, and Cox proportional hazard models; IO status was analyzed using logistic regression.
RESULTS
24,544 patients were analyzed. Overall, 5238 patients (21.3%) who received IO had improved median OS compared with those who did not (20.2 months vs 7.4 months; p<0.0001). Between 2004 and 2010, 9.7% received immunotherapy; from 2011 to 2014, 21.9% received immunotherapy; and from 2015 to 2016, 43.5% received immunotherapy. Three-year OS significantly improved in patients treated with IO across treatment years: 31% (95% CI 29% to 34%) from 2004 to 2010, 35% (95% CI 33% to 37%) from 2011 to 2014, and 46% (95% CI 44% to 48%) from 2015 to 2016 (p<0.0001). Survival was worse in patients who did not receive IO during these treatment years: 16% (15%-17%), 21% (20%-22%), and 27% (25%-28%), respectively. In the overall cohort, age <65 years, female gender, private insurance, no comorbidities, residence in metropolitan area, and treatment at academic centers were associated with better OS (p<0.0001 for all). In the multivariate analysis, receipt of IO from 2015 to 2016 was associated with age <65 years (OR 1.27, 95% CI 1.08 to 1.50), African American race (OR 5.88, 95% CI 1.60 to 28.58), lack of comorbidities (OR 1.43, 95% CI 1.23 to 1.66), and treatment at academic centers (OR 1.44, 95% CI 1.26 to 1.65) (p<0.05 for all).
CONCLUSIONS
OS improved in patients with stage IV melanoma receiving IO, with the highest OS rate in 2015-2016. Our findings, which represent a real-world population, are slightly lower than recent trials, such as KEYNOTE-006 and CheckMate 067. Significant socioeconomic factors may impact receipt of IO and survival.
Identifiants
pubmed: 35998982
pii: jitc-2022-004994
doi: 10.1136/jitc-2022-004994
pmc: PMC9403163
pii:
doi:
Substances chimiques
Immunologic Factors
0
Ipilimumab
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Commentaires et corrections
Type : CommentIn
Informations de copyright
© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.
Références
Ann Surg Oncol. 2018 Dec;25(13):3883-3888
pubmed: 30209727
Lancet Oncol. 2015 Sep;16(9):1049-1060
pubmed: 26206146
J Dermatolog Treat. 2020 Sep;31(6):571-575
pubmed: 31418320
J Clin Epidemiol. 1992 Jun;45(6):613-9
pubmed: 1607900
J Am Acad Dermatol. 2019 Oct;81(4):908-916
pubmed: 31163238
J Cancer Res Clin Oncol. 2017 Mar;143(3):533-540
pubmed: 27878363
Clin Cancer Res. 2009 Sep 1;15(17):5591-8
pubmed: 19671877
JAMA Oncol. 2019 Apr 01;5(4):529-536
pubmed: 30605213
Oncotarget. 2017 Nov 01;8(59):99336-99346
pubmed: 29245905
Nature. 2015 Apr 16;520(7547):373-7
pubmed: 25754329
J Clin Oncol. 2013 Jun 20;31(18):2337-46
pubmed: 23690423
Int J Radiat Oncol Biol Phys. 2017 Sep 1;99(1):22-30
pubmed: 28816150
J Immunol. 2010 Sep 1;185(5):2747-53
pubmed: 20686128
Lancet Oncol. 2016 Nov;17(11):1558-1568
pubmed: 27622997
N Engl J Med. 2019 Oct 17;381(16):1535-1546
pubmed: 31562797
Mod Pathol. 2017 Nov;30(11):1538-1550
pubmed: 28731051
J Am Acad Dermatol. 2019 Apr;80(4):979-989
pubmed: 30365997
Lancet Oncol. 2010 Feb;11(2):155-64
pubmed: 20004617
JAMA. 2016 Apr 19;315(15):1600-9
pubmed: 27092830
Lancet Oncol. 2018 Jun;19(6):737-746
pubmed: 29778737
Oncologist. 2017 Aug;22(8):963-971
pubmed: 28476944
Curr Oncol Rep. 2016 Aug;18(8):47
pubmed: 27287329
Melanoma Res. 2020 Aug;30(4):376-385
pubmed: 32404731
Br J Cancer. 2016 Nov 8;115(10):1193-1200
pubmed: 27711083
Int J Radiat Oncol Biol Phys. 2014 Apr 1;88(5):986-97
pubmed: 24661650